US OptionsDetailed Quotes
BBIO250117P30000
- 0.12
- -1.28-91.43%
15min DelayClose Jan 13 16:00 ET
0.95High0.10Low
0.95Open1.40Pre Close327 Volume1.23K Open Interest30.00Strike Price7.61KTurnover83.11%IV11.41%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type-0.0756Delta0.0500Gamma337.30Leverage Ratio-0.0494Theta-0.0003Rho-25.51Eff Leverage0.0049Vega
BridgeBio Pharma Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER ...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER ...
11
6
3
$BridgeBio Pharma (BBIO.US)$
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
BridgeBio Pharma (NASDAQ: BBIO)reported significant commercial progress for its recently FDA-approved drug Attruby, with 430 prescriptions written by 248 unique physicians for ATTR-CM treatment. The company announced the completion of enrollment in three major Phase 3 clinical trials: FORTIFY (112 patients for LGMD2I/R9), CALIBRATE (70 patients for ADH1), and PROPEL 3 (114 participants f...
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
BridgeBio Pharma (NASDAQ: BBIO)reported significant commercial progress for its recently FDA-approved drug Attruby, with 430 prescriptions written by 248 unique physicians for ATTR-CM treatment. The company announced the completion of enrollment in three major Phase 3 clinical trials: FORTIFY (112 patients for LGMD2I/R9), CALIBRATE (70 patients for ADH1), and PROPEL 3 (114 participants f...
3
$BridgeBio Pharma (BBIO.US)$ https://www.moomoo.com/news/flash/19740696?futusource=news_stock_stockpagenews&ns_stock_id=77584289451605&src=2&stock_news_tab=news&main_broker=WzEwMTdd&my_cid=105069706&client_hour_clock=24&channel=4&skintype=3&level=1&global_content=%7B%22promote_content%22%3A%22mm%3Aflash%3A19740696%22%2C%22invite%22%3A105069706%7D&data_ticket=53ba4dd539203616519b031b3b8738f8
$BridgeBio Pharma (BBIO.US)$ Buy Now it's flying up to 35
2
2
$BridgeBio Pharma (BBIO.US)$ ready for more boomboom candles
1
See FDA PDUFA update 👇
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...
7
1
$BridgeBio Pharma (BBIO.US)$ woot woot, watch FBIO and them for sympathy
NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
65
9
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
李飞Allyssa : Doctor, can you please take a look at LAES?
Jaguar8 OP 李飞Allyssa : Sorry I forgot haha WKEY and LAES are together
李飞Allyssa : Hope it rebounds tomorrow, thank you very much for your efforts![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
152390662 : May I ask where did you see the announcement for $LeddarTech (LDTC.US)$
Jaguar8 OP 152390662 : QUEBEC CITY, Canada, Jan. 13, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVision
, today announced it has wrapped up its presence at the 2025 Consumer Electronics Show (CES) and achieved key strategic milestones. The culmination of the event demonstrates that the company is poised to deliver exceptional value to its customers.
Driving Innovation Through Strategic Partnerships
With the successful CES 2025 demonstration of LeddarVision Surround (LVS-2+) software utilizing Texas Instruments (“TI”) TDA4VH-Q1 processor, LeddarTech has now received the second advanced royalty payment of US$ 3 million as part of its licensing agreement. This partnership, announced in early December 2024, aims to capitalize on the integration of LeddarTech’s groundbreaking LeddarVision software into TI’s scalable portfolio of processors to create a comprehensive platform for advanced driver assistance systems (ADAS) and autonomous driving (AD) markets. The collaboration signifies a pivotal step forward in delivering cutting-edge solutions to automotive OEMs and Tier 1 suppliers, underscoring LeddarTech’s commitment to innovation and leadership.
Customer and Partner Enthusiasm at CES 2025
At CES 2025 in Las Vegas, LeddarTech showcased its LeddarVision Surround-View (LVS-2+), a state-of-the-art software stack tailored for L2/L2+ highway and city ADAS applications. This breakthrough technology addresses critical challenges the automotive industry faces, setting new benchmarks in safety and performance and enabling automotive manufacturers to cost-effectively meet 5-star NCAP 2025/GSR 2022 requirements.
View more comments...